Inventor · disambiguated record
Luca Andrea Lotta
Also filed as: LOTTA LUCA A · LOTTA LUCA ANDREA
12 granted patents·22 pending applications·7 citations·filing 2021–2025
84Inventor score
Top patents by PatentIndex Score
34 records- 0192US11957704B2Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta E (INHBE) inhibitorsREGENERON PHARMA·Filed 2022·Granted Apr 16, 2024·2 cites·11 claims
- 0292US11939635B2Treatment of obesity in subjects having variant nucleic acid molecules encoding Calcitonin Receptor (CALCR)REGENERON PHARMA·Filed 2021·Granted Mar 26, 2024·2 cites·20 claims
- 0391US11759476B2Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Beta E (INHBE) inhibitorsREGENERON PHARMA·Filed 2022·Granted Sep 19, 2023·2 cites·16 claims
- 0485US11359246B2Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitorsREGENERAN PHARMACEUTICALS INC·Filed 2021·Granted Jun 14, 2022·1 cites·29 claims
- 0581US2024252528A1Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0677US12234460B2Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitorsREGENERON PHARMA·Filed 2023·Granted Feb 25, 2025·0 cites·25 claims
- 0777US2025075216A1Treatment Of Muscle Disorder With Folliculin Interacting Protein 1 (FNIP1) Inhibitors And/Or Folliculin (FLCN) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0877US2025129366A1Treatment Of Liver Disease Or Metabolic Disorder With Folliculin Interacting Protein 1 (FNIP1) Inhibitors And/Or Folliculin (FLCN) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0975US2024401136A1Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) Variants And Uses ThereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1075US2024376471A1Treatment of Liver Diseases With Cell Death Inducing DFFA Like Effector B (CIDEB) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1174US2024182973A1Treatment Of Obesity In Subjects Having Variant Nucleic Acid Molecules Encoding Calcitonin Receptor (CALCR)REGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1273US2025188473A1Methods Of Treating Liver Diseases With Phosphodiesterase 3B (PDE3B) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1372US11891607B2Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitorsREGENERON PHARMA·Filed 2022·Granted Feb 6, 2024·0 cites·18 claims
- 1472US2022184114A1Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) InhibitorsREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 1571US12018259B2Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitorsREGENERON PHARMA·Filed 2021·Granted Jun 25, 2024·0 cites·22 claims
- 1670US12123001B2Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitorsREGENERON PHARMA·Filed 2022·Granted Oct 22, 2024·0 cites·14 claims
- 1770US11773393B2Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitorsREGENERON PHARMA·Filed 2022·Granted Oct 3, 2023·0 cites·27 claims
- 1870US2025197866A1Treatment Of Liver Disease With Mitochondrial Glycerol-3-Phosphate Acyltransferase (GPAM) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1966US2022411870A1Treatment Of Obesity With G-Protein Coupled Receptor 75 (GPR75) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2064US12215322B2Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM) inhibitorsREGENERON PHARMA·Filed 2022·Granted Feb 4, 2025·0 cites·3 claims
- 2164US2024158795A1Treatment Of Kidney Diseases With A Combination of Angiopoietin Like 3 (ANGPTL3) Inhibitors And Solute Carrier Family 5 Member 2 (SLC5A2) InhibitorsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2263US12378557B2Treatment of sepsis with PCSK9 and LDLR modulatorsREGENERON PHARMA·Filed 2021·Granted Aug 5, 2025·0 cites·6 claims
- 2363US12049670B2Proprotein convertase subtilisin/kexin type 1 (PCSK1) variants and uses thereofREGENERON PHARMA·Filed 2021·Granted Jul 30, 2024·0 cites·7 claims
- 2463US2025092396A1Treatment Of Osteoarthritis With Cartilage Intermediate Layer Protein 2 (CILP2) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2562US2025236873A1Methods Of Treating Decreased Bone Mineral Density With Cluster Of Differentiation 109 (CD109) InhibitorsREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2661US2025129372A1Treatment Of Osteoarthritis With Procollagen Galactosyl Transferase 2 (COLGALT2) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2761US2023193271A1Treatment Of Kidney Diseases With Angiopoietin Like 3 (ANGPTL3) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2860US2023025878A1Methods Of Treating A Metabolic Disorder With Mitogen-Activated Protein Kinase Kinase Kinase 15 (MAP3K15) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2959US2023021584A1Methods Of Treating Decreased Bone Mineral Density With Kringle Containing Transmembrane Protein 1 (KREMEN1) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3057US2023083558A1Treatment of Decreased Bone Mineral Density With Wnt Family Member 5B (WNT5B) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3157US2023160012A1Treatment of Liver Diseases With CAMP Responsive Element Binding Protein 3 Like 3 (CREB3L3) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3256US2023107173A1Methods Of Treating Chronic Kidney Disease (CKD) With Inhibitors Of Protective Loss-Of-Function GenesREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3355US2023027007A1Treatment of Hypertension With Solute Carrier Family 9 Isoform A3 Regulatory Factor 2 (SLC9A3R2) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3454US2022307033A1Treatment Of Liver Disease With Ring Finger Protein 213 (RNF213) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Luca Andrea Lotta files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →